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Cardiac interstitial fibrosis may contribute to ventricular dysfunction and the prognosis of patients with dilated cardiomyopathy.
The objective of the present study was to determine if total myocardial collagen content and collagen type III/I (III/I ratio) mRNAs
differ in hypertensive, alcoholic, and idiopathic dilated cardiomyopathy subjects. Echocardiography and exercise cardiopulmo-
nary testing were performed in patients with idiopathic (N = 22), hypertensive (N = 12), and alcoholic (N = 11) dilated
cardiomyopathy. Morphometric analysis of collagen was performed in fragments obtained by endomyocardial biopsy with
picrosirius red staining. The collagen III/I ratio was determined by reverse transcription polymerase chain reaction. Samples of
controls (N = 10) were obtained from autopsy. Echocardiographic variables and maximal oxygen uptake were not different
among dilated cardiomyopathy groups. Collagen was higher in all dilated cardiomyopathy groups (idiopathic, hypertensive and
alcoholic, 7.36 ± 1.09%) versus controls (1.12 ± 0.18%), P < 0.05. Collagen was lower in idiopathic dilated cardiomyopathy (4.97
± 0.83%) than hypertensive (8.50 ± 1.11%) and alcoholic (10.77 ± 2.09%) samples (P < 0.005 for both). The collagen III/I ratio
in all samples from dilated cardiomyopathy patients was higher compared to that in controls (0.29 ± 0.04, P < 0.05) but was the
same in the samples from idiopathic (0.77 ± 0.07), hypertensive (0.75 ± 0.07), and alcoholic (0.81 ± 0.16) dilated cardiomyopathy
groups. Because of the different physical properties of the types of collagen, the higher III/I ratio may contribute to progressive
ventricular dilation and dysfunction in dilated cardiomyopathy patients.
Key words: Alcohol; Heart failure; Hypertension; Dilated cardiomyopathy; Collagen
H.N. Soufen was the recipient of a doctoral fellowship from FUNCOR-SBC. I.M.S. Aneas is the recipient of a doctoral fellowship
from FAPESP (#01/01295-7). J.E. Krieger is supported by grants from FAPESP (#01/00009-0) and CNPq (#471219/01-0).
Received January 21, 2008. Accepted November 25, 2008
Introduction
Left ventricular systolic dysfunction represents the final
common pathway of several heart injury disorders (1).
Despite recent major therapeutic advances, chronic heart
failure still has a poor prognosis. Knowledge on the under-
lying cause of the cardiomyopathy has prognostic value
(2-6). Mortality in patients with similar degrees of conges-
tive heart failure and left ventricular dilatation due to alco-
holic cardiomyopathy is significantly lower than that for
patients with idiopathic cardiomyopathy (5). The cause of
this difference is unknown.
In the normal adult heart, approximately 2-4% of the
myocardium is collagen. Of the main collagen types, the
major fibrillar collagens are types I and III, which are
essential components of the cardiovascular extracellular
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matrix, maintaining myocardium structural and functional
integrity (7-9). Collagen synthesis begins in the fibroblast.
The disproportionate accumulation of fibrillar collagen in
the interstitial space of the ventricle has been thought to be
responsible for abnormal myocardial stiffness and for the
impaired pumping capacity of the heart (7,9,10). Because
of their different physical properties, an altered collagen
type III/I ratio (III/I ratio) may therefore have a major impact
on the diastolic and systolic function of the heart and may
influence the overall alterations occurring during the pro-
gression of the disease (7,11). Whereas collagen type III
represents about 11% of total collagen, and is character-
ized by thin fibers that present great elasticity (such as
skin), collagen type I represents about 85% of total col-
lagen, and is characterized by thick fibers that confer
stiffness and resistance to stretch and deformation (such
as tendon) (12).
A better understanding of the natural history of this
remodeling process might permit better risk assessment
and a more specific intervention earlier in this disease
process, before it becomes irreversible. The increase in
collagen content in hypertensive, alcoholic, and idiopathic
dilated cardiomyopathy is well documented in studies of
postmortem tissue (12,13). However, because definitive
data on collagen content and type in different forms of
cardiomyopathy are limited, we determined the collagen
content and the ratio of collagen subtype messenger RNAs
(mRNAs) in endomyocardial biopsy samples from patients
with dilated cardiomyopathy due to hypertension, alcohol-
ism, and idiopathic cardiomyopathy and compared them
with samples from the control group.
Patients and Methods
Study cohort
Forty-five consecutive patients [36 (80%) males, 44 ±
13 years] with dilated cardiomyopathy were selected for
this study.
All patients were receiving optimized treatment with
angiotensin-converting enzyme inhibitors and had left ven-
tricular ejection fraction less than 0.50 with diffuse hypoki-
nesis on echocardiography.
Patients were excluded from the study if one of the
following criteria were met: coronary heart disease; cor
pulmonale; valvular heart disease; pericardial disease;
Chagas heart disease; diabetes mellitus; creatinine levels
above 2 mg/dL; coagulopathies; onset of cardiomyopathy
during the last month of pregnancy or within 5 months of
delivery; a history of treatment with cardiotoxic drugs;
presence of active or borderline myocarditis in the endo-
myocardial biopsy fragments according to the Dallas crite-
ria (14), and use of β-blockers, aldosterone antagonists, or
spironolactone at any time before the study.
All procedures were carried out in accordance with
institutional guidelines, and an Ethics Review Committee
approved the protocol. All patients gave written informed
consent before entering the study.
Assignment of cause
Patients were allocated into groups based on the cause
of the cardiomyopathy. Idiopathic dilated cardiomyopathy
was designated as the primary cause when no other cause
of dysfunction was apparent after a full-noninvasive workup.
Hypertensive cardiomyopathy was assigned as the pri-
mary cause when there was a history of poorly controlled
hypertension of more than 5 years’ duration. All study
patients had a systolic blood pressure above 180 mmHg or
a diastolic blood pressure above 110 mmHg, or both of
these. Alcoholic cardiomyopathy was assigned as the
primary cause in the presence of heavy alcohol use, de-
fined as the consumption of more than 100 g/day of etha-
nol for 6 months before the onset of heart failure.
Endomyocardial biopsy
An endomyocardial biopsy was performed on all pa-
tients with a Caves-Schultz bioptome to exclude myocardi-
tis by way of the right internal jugular vein. In each case,
three to ten fragments (mean of six fragments) were ob-
tained from the interventricular septum of the right ven-
tricle. One fragment was immediately placed in 10% for-
malin for light microscopy and picrosirius red staining. The
fresh sample was immediately frozen.
Duration of symptoms
The duration of cardiac heart failure was defined as the
time from the onset of subjective symptoms (dyspnea on
exertion, paroxysmal nocturnal dyspnea, orthopnea and/
or edema) to the day of the endomyocardial biopsy.
Echocardiography
Left ventricular measurements were taken according to
the recommendations of the American Society of Echocardi-
ography (15). Measurements included left ventricular end-
diastolic and end-systolic dimension obtained by M-mode
echocardiography of the left ventricle in the short-axis view
at the level of the papillary muscle. The cube of the end-
diastolic dimension was used as an estimation of the end-
diastolic volume and the cube of the end-systolic dimension
as an estimation of end-systolic volume. Stroke volume was
derived from the difference between end-diastolic and end-
systolic volume. Ejection fraction was calculated as the ratio
of stroke volume to end-diastolic volume.
1100
Braz J Med Biol Res 41(12) 2008
H.N. Soufen et al.
www.bjournal.com.br
Cardiopulmonary exercise testing
Symptom-limited exercise testing together with a respi-
ratory gas exchange analysis was performed using a bi-
cycle ergometer (Medfit, Medical Fitness Equipment, Neth-
erlands) at a constant pedaling speed of 60 rpm with
workload increments of 15 W every 3 min to measure the
maximal oxygen uptake (16).
Control group
Hearts from 3 females and 7 males (48 ± 13 years) with
no cardiac disease were sampled at necropsy. Right ven-
tricular specimens were obtained from the interventricular
septum within 10 h after death. All patients died from extra
cardiac causes. The hearts were considered to be normal
at necropsy. In addition, the samples obtained at necropsy
were negative for RNA degradation measured by Northern
blot analysis.
Collagen quantification (collagen volume fraction)
Histological sections of the endomyocardial biopsies
and control samples (10 µm thick) were cut and stained
with Sirius-red F3BA (0.5% in saturated aqueous picric
acid). A single investigator who was unaware of the nature
of the experimental groups performed computer-assisted
morphometry (Quantimet 520, Image Analysis System,
Cambridge Instruments, UK). For each sample, all fields
were analyzed (6.7 ± 2.8 fields) with 10X objective lens
under transmitted light. Collagen volume fraction (CVF)
was calculated as the sum of all connective tissue areas
divided by the sum of all connective tissue plus muscle
areas in all fields. Collagen surrounding intramyocardial
coronary arteries was excluded from the calculation. An-
other independent investigator randomly analyzed some
of the samples. Intra- and interobserver variability were
within 10%. This morphometric approach for measure-
ment of fibrillar collagen within the cardiac interstitium has
been validated previously (7,17). The total CVF is closely
related to hydroxyproline content of the tissue (18,19).
Determination of the mRNAs of collagen types I and III
The ratio of collagen type III/I mRNAs was determined by
reverse transcription-polymerase chain reaction (RT-PCR).
Total RNA was isolated from frozen myocardial tissue
by the gonidium acid thiocyanate/phenol/chloroform ex-
traction method. mRNAs (300 ng) were reverse transcribed
into cDNA with oligo (dT) and avian-myeloblastosis virus
reverse transcriptase in a 20-µL final volume. Amplification
of 1 µL of the reverse products was carried out with primers
for the human α 1(III) collagen (11,20) (upper primer 5'-
TGGTGTTGGAGCCGCTGCCA-3'; lower primer 5'-
CTCAGCACTAGAATCTGTCC-3'; product length 376 bp)
and for human α 1(I) collagen (upper primer 5'-GGCGGCC
AGGGCTCCGACCC-3'; lower primer 5'-ATTCCTGGTCT
GGGGCACC-3'; product length 347 bp). Specificity of the
amplified products was confirmed by sequencing. Primer
sequences were selected to correspond to 2 different
exons, separated by an intron, in order to permit identifica-
tion of undesired genomic DNA amplification. The primers
used for RT-PCR were located at the C-terminal end of the
propeptides. In this region, the sequences are highly con-
served. To make quantitative measurements of the mRNAs
for collagen types I and III, cDNA for both collagen sub-
types was co-amplified simultaneously in a single PCR. All
PCRs were carried out in a 50-µL volume. The mixture
contained 25 pM each of collagen primer, 1.25 mM dNTP,
50 mM KCl, 2 mM MgCl2, 10 mM Tris-HCl, pH 9.0, 0.1%
Triton X-100, 2.5 U AmpliTaq polymerase. Each sample
was incubated for 30 cycles, each cycle consisting of a
denaturing step at 94°C for 1 min, primer annealing at 58°C
for 1 min, and an extension at 72°C for 1 min. After a final
extension step at 72°C for 10 min, the samples were stored
at 4°C. The proportion of synthesized RT-PCR products of
collagen types III and I was constant for 25, 30, or 35 cycles
of RT-PCR. Therefore, 30 cycles of the RT-PCR were used
for further analysis. The PCR fragments were analyzed by
polyacrylamide gel electrophoresis and visualized by Sybr
gold staining. The band intensities of type III and type I
collagens were quantified by densitometry scanning. The
ratio of collagen types I and III was determined as the ratio
of the density of corresponding mRNA bands.
Statistical analysis
Data are reported as means ± SD. Data comparisons
were made by analysis of variance. Post hoc pair-wise
group comparisons were carried out with Duncan’s mul-
tiple range test. The correlation between the characteris-
tics of the myocardial interstitium (CVF and the relative
amounts of the mRNAs of collagen subtypes III and I) and
the left ventricular ejection fraction was determined with
Pearson’s correlation method. Significance level was as-
sumed to be P < 0.05. Statistical analysis was performed
with SPSS v 9 (SPSS Inc., USA).
Results
Patient characteristics
The 45 patients had a mean ± SD ejection fraction of
34.1 ± 0.88% and were assigned to the idiopathic dilated
cardiomyopathy (N = 22), hypertensive (N = 12), or alco-
holic heart disease (N = 11) group according to the criteria
described in Methods.
There were no differences among the three dilated
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cardiomyopathy groups regarding gender, age, duration
of heart failure, end-diastolic and end-systolic diameter
of the left ventricle or left ventricular ejection fraction,
and maximal oxygen uptake. Baseline characteristics in
the dilated cardiomyopathy and control groups are shown
in Table 1. Routine histological analysis of the endomyo-
cardial biopsy showed myocyte hypertrophy and intersti-
tial fibrosis but no evidence of active or borderline myo-
carditis.
Collagen volume fraction
As expected, myocardial collagen volume fraction was
higher in samples from patients with dilated cardiomyopa-
thy from all causes (7.36 ± 1.09%) versus controls (1.12 ±
0.18%, P < 0.05). However, the CVF differed among these
groups (P = 0.0001), being lowest in idiopathic (4.97 ±
0.83) compared with hypertensive (8.50 ± 1.11%, P <
0.05) and alcoholic (10.77 ± 2.09%) samples (P < 0.05).
Figure 1 shows interstitial collagen of myocardium frag-
ments of idiopathic, hypertensive, and alcoholic dilated
cardiomyopathies, and control groups.
Collagen type I and III mRNAs
The ratio of the mRNAs in the dilated cardiomyopathy
samples from all causes was higher than that in controls
(0.29 ± 0.04, P < 0.05). There was no statistical difference
in this ratio among the different cardiomyopathies (0.77 ±
0.07 for idiopathic; 0.75 ± 0.07 for hypertensive; 0.81 ±
0.16 for alcoholic; P > 0.05). Figure 2 shows gel electro-
phoresis of PCR products of three experiments.
Because the ratio of collagen type III/I mRNAs was
higher in dilated cardiomyopathy, but was not different
among the different cardiomyopathies, we determined
whether the ratio correlated with left ventricle ejection
fraction of the three groups of patients. Figure 3 shows the
positive correlation between left ventricular ejection frac-
tion and collagen III/I ratio mRNA in all dilated cardiomyop-
athy groups (r = 0.44, P = 0.005). Similar analysis with total
collagen volume fraction did not correlate with left ventric-
ular ejection fraction (r = 0.17, P = 0.30; data not shown).
Figure 1. Representative fields of Sirius red-
stained sections of myocardium under 10X stand-
ard light magnification. A, Idiopathic; B, hyperten-
sive; C, alcoholic; D, control. The interstitial col-
lagen appears darker than myocytes in these
black and white photographs (arrows). Scale bar
= 100 µm for all panels.
Table 1. Baseline characteristics of the idiopathic, hypertensive, and alcoholic dilated cardiomyopathy and control groups in the
present study.
Parameter Idiopathic (N = 22) Hypertensive (N = 12) Alcoholic (N = 11) Control (N = 10)
Age (years) 40.54 ± 15.08 52.08 ± 11.31 42.45 ± 8.18 48.00 ± 13.01
Duration of symptoms (months) 32.59 ± 34.35 52.17 ± 48.33 51.36 ± 29.89 -
VO2max (mL·kg-1·min-1) 11.38 ± 2.77 12.64 ± 3.42 11.26 ± 2.28 -
LVEDV (mL) 71.41 ± 7.72 69.58 ± 6.27 75.63 ± 11.37 -
LVESV (mL) 62.67 ± 7.48 59.75 ± 6.34 66.30 ± 10.85 -
LVEF (%) 32.23 ± 5.33 36.17 ± 5.44 35.81 ± 6.64 -
Data are reported as means ± SD. VO2max = maximal oxygen uptake; LVEDV = left ventricle end-diastolic volume; LVESV = left
ventricle end-systolic volume; LVEF = left ventricle ejection fraction. *There were no statistically significant differences of any of the
variables among the groups (Kruskal-Wallis test and Duncan multiple range test).
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Figure 2. Gel electrophoresis of polymerase chain reaction prod-
ucts visualized by Sybr gold staining. M indicates DNA molecular
weight markers. N indicates negative control. Col III, Col I =
collagen types III and I. Data are representative of three experi-
ments.
Figure 3. Linear regression between left ventricle ejection frac-
tion and ratio of collagen type III/I mRNAs determined by RT-
PCR in all patients with dilated cardiomyopathy (DC; Pearson’s
correlation coefficient = 0.44, P = 0.005). The different patient
groups are indicated by squares for idiopathic, triangles for hy-
pertensive, and circles for alcoholic disease.
Discussion
Collagen quantification
The myocardial collagen content in dilated cardiomy-
opathy samples was higher than that observed in control
hearts, which agrees with previous data from postmortem
tissues (9,21). This occurred in spite of the use of high
doses of angiotensin-converting enzyme inhibitors. Ex-
perimental studies show that these drugs are able to
prevent and revert cardiac dysfunction and remodeling,
even restoring myocardial structure to normal (10,12,22-
24). The fact that all patients were receiving optimized
treatment is consistent with the idea that the renin-angio-
tensin-aldosterone system is not the only determinant of
myocardial fibrosis, stressing the importance of other mod-
ulating factors triggered by neurohumoral activation lead-
ing to myocyte necrosis and apoptosis. These results
agree with the findings of Brilla et al. (25) showing that in 35
patients with hypertensive heart disease, the angiotensin-
converting enzyme inhibitor treatment partially reduced
the quantity of fibrosis, improved diastolic function, but
CVF remained abnormal.
The collagen content of the samples of alcoholic and
hypertensive cardiomyopathy patients was higher than
that observed in patients with idiopathic dilated cardiomy-
opathy. Data from the literature show that, compared with
patients with idiopathic dilated cardiomyopathy, patients
with alcoholic and hypertensive cardiomyopathy have a
better survival rate (5). One may speculate that the loss of
collagen fibers from the matrix could lead to progressive
dilation and impairment of cardiac pump performance,
because the myocytes are not properly linked. Thus, under
these conditions, less collagen content may be associated
with a worse prognosis for cardiomyopathic hearts, point-
ing to a relevant role for metalloproteinases in this process
(26,27). Alterations in the interstitium are extremely com-
plex, and the dynamic balance between the matrix synthe-
sis and degradation may influence cardiac performance in
a not so simple way. In addition, the higher amount of
fibrosis observed in patients with alcoholic dilated cardio-
myopathy may explain, at least in part, the higher preva-
lence of arrhythmia in these patients (28).
Collagen type III/I expression ratio
In this study, the myocardial ratio of collagen type III/I
mRNAs of the dilated cardiomyopathy samples was higher
than that observed in the normal myocardial tissue. This
conversion in collagen types appears to be a characteristic
feature of early collagen formation. In myocardial infarc-
tion, during early healing, the new collagen is mostly thin
type III, and is susceptible to stretch by 15 weeks. Then,
there is a replacement by type I with a greater resistance to
distension (29,30). In hypertensive myocardial fibrosis,
there is an initial deposition of collagen type III, followed by
type I (12,13,31). Type III collagen is also increased in
many experimental cardiac diseases (7,14,32-36). In hu-
man cardiac samples, the results have been controversial.
Weber et al. (21), studying hearts with idiopathic cardiomy-
opathy, observed a larger proportion of thin fibers, prob-
ably type III, which may contribute to dilation and loss of
function. In contrast, the proportion between types III and I
was reduced in samples obtained from explanted hearts
with dilated cardiomyopathy (37), while cardiac samples
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obtained at autopsy from hypertensive patients showed a
disproportionate increase of collagen III (31).
In the present study, we found a positive correlation
between the left ventricular ejection fraction and III/I ratio.
Considering that all patients presented systolic dysfunc-
tion, we demonstrated that with more type I collagen, which
is associated with strength and stiffness, the left ventricular
ejection fraction is worse. On the other hand, a previous
study of dilated cardiomyopathy with left ventricular ejec-
tion fraction lower than 50% presented increased I/III ratio,
and related this finding to systolic and diastolic dysfunction
(38). What seems to be contradictory, at first analysis, is
that the normal myocardium had a lower proportion of
collagen III/I mRNA compared with that in the dilated
cardiomyopathy groups. Based on these results, it is pos-
sible that with dilated cardiomyopathy evolution, a reduc-
tion in proportion between collagens III and I occurs, but
this proportion is never equal to that observed in normal
tissue. In other words, the scar matures, but can never
complete this process, because new aggressive stimuli
may trigger an endless new cycle.
Based on our results, the next step is the application of
this information for new therapeutic interventions.
Limitations of this study
A limitation of the present study is that the findings
obtained from the analysis of the right ventricle endomyo-
cardial biopsy samples may not represent the structural
alterations taking place in the whole organ. However, data
from the literature support the idea that, in dilated cardio-
myopathy, the myocardial damage is homogeneous, thus
reducing the weight of such a limitation (39).
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